|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Pfizer Vicuron Pharmaceuticals |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00041704 |
Purpose
Anidulafungin is an antifungal agent of the echinocandin class which is highly active in vitro against fluconazole resistant Candida species. The efficacy of anidulafungin has demonstrated in various animal models of fluconazole-resistant mucosal disease; as well as, in Phase 2 Esophageal Candidiasis studies. This study is intended to offer patients with FRMC an alternate therapy with amphotericin B or with other agents whose efficacy and/or safety are inadequate in the treatment of this disease.
| Condition | Intervention | Phase |
|
Candidiasis |
Drug: Anidulafungin, VER002 |
Phase II |
| MedlinePlus related topics: | Yeast Infections |
| ChemIDplus related topics: | Anidulafungin |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Phase 2 Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis. |
Eligibility
| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Pennsylvania | |||||
| Versicor, Inc. | |||||
| King of Prussia, Pennsylvania, United States, 19406 | |||||
| Pfizer |
| Vicuron Pharmaceuticals |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Link to ClinicalStudyResults.org Posting 
  |
| Study ID Numbers: | VER002-11 |
| First Received: | July 12, 2002 |
| Last Updated: | April 26, 2007 |
| ClinicalTrials.gov Identifier: | NCT00041704 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|